

## **AMENDMENTS TO THE CLAIMS**

Please cancel Claims 1-10 without prejudice and insert therefore new Claims 11-22. This listing of claims will replace all prior versions, and listings, of claims in the application.

### **Listing of Claims:**

Claims 1-10 (canceled)

11. (new) A method for increasing the level of endogenous growth hormone in a mammal in need thereof, comprising administering a dipeptidyl peptidase IV inhibitor, or a pharmaceutically acceptable salt thereof, and a growth hormone secretagogue, or a pharmaceutically acceptable salt thereof, wherein the level of endogenous growth hormone in the mammal is greater than the level resulting from an equivalent dose of the growth hormone secretagogue alone.

12. (new) The method of Claim 11 wherein the mammal is selected from the group consisting of humans, horses, cattle, dogs, cats, rats, mice, pigs, goats, sheep, rabbits and monkeys.

13. (new) The method of Claim 12 wherein the mammal is a human.

14. (new) The method of Claim 13 wherein the human is an elderly human.

15. (new) The method of Claim 13 wherein the dipeptidyl peptidase IV inhibitor is 7-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo[4,3- $\alpha$ ]pyrazine, or a pharmaceutically acceptable salt thereof, and the growth hormone secretagogue is ibutamoren, or a pharmaceutically acceptable salt thereof.

16. (new) A method for the treatment, control, amelioration, or reduction of risk of a disease or disorder associated with growth hormone deficiency in a mammal in need thereof by administering a dipeptidyl peptidase IV inhibitor, or a pharmaceutically acceptable salt thereof, and a growth hormone secretagogue, or a pharmaceutically acceptable salt thereof.

17. (new) The method of Claim 16 wherein the disease or disorder is growth retardation associated with growth hormone deficiency.

18. (new) The method of Claim 17 wherein the disease or disorder is a metabolic disorder associated with growth hormone deficiency.

19. (new) The method of Claim 18 wherein disease or disorder is an injury, trauma, burn, a wound in need of healing, or a patient recovering from surgery.

20. (new) The method of Claim 16 wherein the dipeptidyl peptidase IV inhibitor is 7-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo[4,3- $\alpha$ ]pyrazine, or a pharmaceutically acceptable salt thereof, and the growth hormone secretagogue is ibutamoren, or a pharmaceutically acceptable salt thereof.

21. (new) A pharmaceutical composition comprising a dipeptidyl peptidase IV inhibitor, or a pharmaceutically acceptable salt thereof, and a growth hormone secretagogue, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

22. (new) The pharmaceutical composition of Claim 21 wherein the dipeptidyl peptidase IV inhibitor is 7-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo[4,3- $\alpha$ ]pyrazine, or a pharmaceutically acceptable salt thereof, and the growth hormone secretagogue is ibutamoren, or a pharmaceutically acceptable salt thereof.